Anti-TIGIT mAb treatment has been shown to escalate the proliferation, cytokine production, and degranulation of bone marrow CD8+ T cells from MM patients and peripheral blood CD8+ T cells from melanoma patients (125, 136). This evidence concerns the gene CD8A and melanoma.